Sued-Chemie to close Swiss production plant

Published: 10-Sep-2010
Packaging Finance

Economically unviable operations force closure by end of 2010


Süd-Chemie, of Munich in Germany, in accordance with its joint venture partner PQH Holding, of Fribourg in Switzerland, is planning to cease production at its Swiss subsidiary Süd-Chemie (Schweiz) by the end of 2010 due to ‘continuing financial losses under very difficult market conditions’.

The site in Romont manufactures tubes for protective packaging solutions mainly for the pharmaceutical and the nutraceutical industry and currently has 36 employees. The company was established as a joint venture between Süd-Chemie (51%) and PQH Holding (49%).

Since its foundation in 2006, Süd-Chemie (Schweiz) has been suffering from ongoing economically unviable operations and underemployed production capacities. The market situation was additionally affected by aggressive competition from low-priced East European products.

Süd-Chemie therefore needs to consolidate its production capacities and envisages stopping production at Romont prior by the end of 2010. Some of the current production would be transferred to Süd-Chemie's pharma packaging production site in Romorantin in France.

  • Companies:
  • Sued-Chemie AG
See more

You may also like

Manufacturing

Clariant plans acquisition of Süd-Chemie

Read more
Turns 2009 net loss into net income of CHF180m

Trending Articles

  1. Small molecules: big market opportunities The rapid rise of biologic drugs in recent years has been accompanied by a market narrative that suggests that innovation and new treatments will be fuelled by breakthroughs in this area, leading to a decline in the small molecule pipeline. This is far from true, notes Kevin Cook, Chief Executive Officer at Sterling Pharma Solutions; both are increasing and small molecule drugs continue to be a mainstay of many drug development portfolios
  2. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    The pros and cons of distribution agreements For life sciences companies seeking to break into overseas markets, distribution agreements are central to success
  4. Lonza appoints President of Capsules and Health Ingredients Christian Seufert joins from BASF, where he has worked for the last 20 years. Most recently, he held the role of Senior VP for the Global Business Unit Pharma Solutions

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Manufacturing

Clariant plans acquisition of Süd-Chemie

Turns 2009 net loss into net income of CHF180m
Drug Delivery

Adult vaccination programmes deliver significant socio-economic benefits, study finds

The study shows that adult immunisation programmes return 19x their initial investment, which could ease the pressure on health systems
Distribution

How efficient logistics can change the lives of rare disease patients

Envirotainer’s Dr Danial Arkwell, Head of Global Key Accounts, Pharma, highlights the vital role of efficient logistics when getting orphan drugs to patients in desperate need
Packaging

Schreiner Group establishes Jinshan site

The expansion allows the company to enhance its global competitiveness
Regulatory

Policy vacuum risks UK becoming a medicines supply backwater

The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
Hi Tech Manufacturing

Johnson Matthey agrees to sell Medical Device Components business

The business has been sold to Montagu Private Equity for USD $700m
Finance

Fusion Pharmaceuticals to be acquired by AstraZeneca for up to $2.4bn

Fusion developed a Targeted Alpha Therapies platform together with linker technology to selectively deliver cancer therapies
Subscribe now